FDA approves second antiviral COVID pill
Merck’s drug, molnupiravir, was found to reduce hospitalizations and deaths by 30 percent, while Pfizer's antiviral pill had a nearly 90 percent reduction.
Author
Eddie Burkhalter is a reporter at the Alabama Political Reporter. You can email him at [email protected] or reach him via Twitter.